BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 143-148

  Diehl, V ^a   Sieber, M ^a   Ruffer U ^a   Lathan, B ^a   Hasenclever, D ^e   Pfreundschuh, M ^b   Loeffler, M ^e   Lieberz, D ^a   Koch, P ^c   Adler, M ^d   Tesch, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

BEACOPP; chemotherapy; Hodgkin's disease

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HODGKIN DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 8044250873     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008294312741     Document Type: Article

References (24)

1. De Vita VT, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-95.
2. Bonadonna G, Zucali R. Monfardini S et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin. vinblastine, and imidazole carboximide versus MOPP. Cancer 1975; 36: 22-259.
3. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med 1986; 104: 739-46.
4. Canellos GP, James MD. Anderson JR et al. Chemotherapy of advanced Hodgkin's disease with MOPP. ABVD. or MOPP alternating with ABVD. N Engl J Med 327; 1992: 1478-84.
5. Diehl V, Loeffler M, Pfreundschuh M et al. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherpy in patients with advanced Hodgkin's disease. Ann Oncol 1995; 6: 901-10.
6. Longo DL: The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol 1990; 17: 716-35.
7. Van Rijswijk RE, Haanen C. Dekker AW et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776-82.
8. De Vita VT, Hubbard SM, Longo DL. The chemotherapy of lymphomas: Looking back, moving forward the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1987; 47: 5810-24.
9. Carde P, MacKintosh R, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP therapy. J Clin Oncol 1983; 1: 146-53.
10. Hasenclever D, Loeffler M, Diehl V for the German Hodgkin's Lymphoma Study Group. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 1996; 7 (Suppl 4): 95-8.
11. Diehl V. Dose escalation study for the treatment of Hodgkin's disease. Ann Hematol 1993; 66: 139-40.
12. Carbone PP, Kaplan HS, Musshoff K et al. Report of the committee on Hodgkin's disease staging. Cancer Res 1971; 31: 1860-1.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
14. Hasenclever D, Schmilz N, Diehl V for the German Hodgkin's Lymphoma Study Group. Is there a rationale for high-dose chemotherapy as first line treatment of advanced Hodgkin's disease? Leuk Lymph 1995; 15 (Suppl 1): 47-9.
15. Fuchs R, Loeffler M, Pfreundschuh M et al. Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. Leuk Lymph 1994; 14: 79-89.
16. Pfreundschuh M, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580-6.
17. Hancock BW, Vaughan Hudson G, Vaughan Hudson B et al. BNLI randomised study of MOPP against LOPP in advanced Hodgkin's disease long-term results. Br J Cancer 1991; 63: 579-82.
18. Selby P, Patel P, Milan S et al. ChIVPP combination chemotherapy for Hodgkin's disease: Long-term results. Br J Cancer 1990; 62: 279-85.
19. Cooper RM, Pajak TF, Nissen NI et al. A new effective four-drug combination of CCNU, vinblastine, prednisoneand procarbazine for the treatment of advanced Hodgkin's disease. Cancer 1980; 46: 654.
20. Tesch H, Brosteanu O, Hasenclever D et al. Comparison of COPP/ABVD and COPP ABV IMEP in the treatment of Hodgkin's disease. Results of HD 5 and HD 6 studies of the German Hodgkin Study Group. Ann Oncol 1996; 7 (Suppl 3): Abstr 170.
21. Klimo P, Connors JM. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988; 25: 34-40.
22. Connors JM, Klimo P, Adams G et al. MOPP/ABV hybrid versus alternating MOPP/ABVD for advanced Hodgkin's disease. Proc Am Soc Clin Oncol 1992; 11: 317 (Abstr 1073).
23. Viviani S, Bonadonna G, Santoro A et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 1996; 14: 1421-30.
24. O'Reilly SE, Klimo P, Connors JM. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer 1991; 67: 271-80.